The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

Palbociclib was approved by the United States Food and Drug Administration for use, in combination with letrozole, as a first-line treatment for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) postmenopausal metastatic breast cancer. However, recent studies s...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Han, Wu, Zhuo-Xun, Lei, Zi-Ning, Teng, Qiu-Xu, Yang, Yuqi, Ashby, Charles R., Lei, Yixiong, Lian, Yuyin, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957877/
https://www.ncbi.nlm.nih.gov/pubmed/35350768
http://dx.doi.org/10.3389/fphar.2022.861642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957877/
https://www.ncbi.nlm.nih.gov/pubmed/35350768
http://dx.doi.org/10.3389/fphar.2022.861642

Ejemplares similares